Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2019

01-09-2019 | Acute Lymphoblastic Leukemia | Review Article

ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis

Authors: Ju-Le Yang, Yi-Ni Liu, Yong-Yi Bi, Hong Wang

Published in: International Journal of Hematology | Issue 3/2019

Login to get access

Abstract

Genome-wide association studies have implicated several single-nucleotide polymorphisms (SNPs) in the AT-rich interactive domain 5B (ARID5B) gene in children with ALL; however, whether ARID5B variants (rs10821936, rs10994982, rs7089424) are associated with childhood ALL remains controversial. We performed this study to obtain more conclusive results. Eligible studies were searched in PubMed, Web of Science, and EMBASE. Odds ratios and 95% confidence intervals were calculated. A total of 26 studies were included. Analyses stratified by ethnicity revealed that three polymorphisms are significantly associated with the odds of childhood ALL in Caucasians, and rs10994982 and rs7089424 with the odds of childhood ALL in Asian populations. Furthermore, subtype analyses provided strong evidence that the three polymorphisms are highly associated with the risk of B-cell ALL. Our findings indicate that the ARID5B variants (rs10821936, rs10994982, rs7089424) are significantly associated with the risk of childhood ALL.
Literature
1.
Linabery AM, Blommer CN, Spector LG, Davies SM, Robison LL, Ross JA. ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Leuk Res. 2013;37(8):936–42.CrossRefPubMedPubMedCentral
2.
Jiang Y, Hou J, Zhang Q, Jia ST, Wang BY, Zhang JH, et al. The MTHFR C677T polymorphism and risk of acute lymphoblastic leukemia: an updated meta-analysis based on 37 case-control studies. Asian Pac J Cancer Prev. 2013;14(11):6357–62.CrossRefPubMed
3.
Ross JA, Linabery AM, Blommer CN, Langer EK, Spector LG, Hilden JM, et al. Genetic variants modify susceptibility to leukemia in infants: a Children’s Oncology Group report. Pediatr Blood Cancer. 2013;60(1):31–4.CrossRefPubMed
4.
Huang X, Ma D, Dong W, Li P, Lu T, He N, et al. Gene expression profiling of the DNMT3A R882 mutation in acute leukemia. Oncol Lett. 2013;6(1):268–74.CrossRefPubMedPubMedCentral
5.
Imai K. Acute lymphoblastic leukemia: pathophysiology and current therapy. Rinsho Ketsueki. 2017;58(5):460–70.PubMed
6.
Trevino LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1001–5.CrossRefPubMedPubMedCentral
7.
Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1006–10.CrossRefPubMedPubMedCentral
8.
Huang TH, Oka T, Asai T, Okada T, Merrills BW, Gertson PN, et al. Repression by a differentiation-specific factor of the human cytomegalovirus enhancer. Nucleic Acids Res. 1996;24(9):1695–701.CrossRefPubMedPubMedCentral
9.
Wilsker D, Patsialou A, Dallas PB, Moran E. ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 2002;13(3):95–106.PubMed
10.
Wang Y, Chen J, Li J, Deng J, Rui Y, Lu Q, et al. Association of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of childhood acute lymphoblastic leukemia in a Chinese population. Gene. 2013;524(2):203–7.CrossRefPubMed
11.
Lin CY, Li MJ, Chang JG, Liu SC, Weng T, Wu KH, et al. High-resolution melting analyses for genetic variants in ARID5B and IKZF1 with childhood acute lymphoblastic leukemia susceptibility loci in Taiwan. Blood Cells Mol Dis. 2014;52(2–3):140–5.CrossRefPubMed
12.
Urayama KY, Takagi M, Kawaguchi T, Matsuo K, Tanaka Y, Ayukawa Y, et al. Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese. Sci Rep. 2018;8(1):789.CrossRefPubMedPubMedCentral
13.
Kreile M, Rots D, Zarina A, Rautiainen L, Visnevska-Preciniece Z, Kovalova Z, et al. Association of ARID5B genetic variants with risk of childhood B cell precursor acute lymphoblastic leukaemia in Latvia. Asian Pac J Cancer Prev. 2018;19(1):91–5.PubMedPubMedCentral
14.
Archer NP, Perez-Andreu V, Stoltze U, Scheurer ME, Wilkinson AV, Lin TN, et al. Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. PLoS One. 2017;12(8):e0180488.CrossRefPubMedPubMedCentral
15.
Al-Absi B, Noor SM, Saif-Ali R, Salem SD, Ahmed RH, Razif MF, et al. Association of ARID5B gene variants with acute lymphoblastic leukemia in Yemeni children. Tumour Biol. 2017;39(4):1010428317697573.CrossRefPubMed
16.
Kreile M, Piekuse L, Rots D, Dobele Z, Kovalova Z, Lace B. Analysis of possible genetic risk factors contributing to development of childhood acute lymphoblastic leukaemia in the Latvian population. Arch Med Sci. 2016;12(3):479–85.CrossRefPubMedPubMedCentral
17.
Bhandari P, Ahmad F, Mandava S, Das BR. Association of genetic variants in ARID5B, IKZF1 and CEBPE with risk of childhood de novo B-lineage acute lymphoblastic leukemia in India. Asian Pac J Cancer Prev. 2016;17(8):3989–95.PubMed
18.
Bekker-Mendez VC, Nunez-Enriquez JC, Torres Escalante JL, Alvarez-Olmos E, Gonzalez-Montalvoc PM, Jimenez-Hernandez E, et al. ARID5B, CEBPE and PIP4K2A germline genetic polymorphisms and risk of childhood acute lymphoblastic leukemia in Mexican patients: a MIGICCL study. Arch Med Res. 2016;47(8):623–8.CrossRefPubMed
19.
Evans TJ, Milne E, Anderson D, de Klerk NH, Jamieson SE, Talseth-Palmer BA, et al. Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures. PLoS One. 2014;9(10):e110255.CrossRefPubMedPubMedCentral
20.
Xu H, Yang W, Perez-Andreu V, Devidas M, Fan Y, Cheng C, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013;105(10):733–42.CrossRefPubMedPubMedCentral
21.
Gutierrez-Camino A, Lopez-Lopez E, Martin-Guerrero I, Sanchez-Toledo J, Garcia de Andoin N, Carbone Baneres A, et al. Intron 3 of the ARID5B gene: a hot spot for acute lymphoblastic leukemia susceptibility. J Cancer Res Clin Oncol. 2013;139(11):1879–86.CrossRefPubMed
22.
Chokkalingam AP, Hsu LI, Metayer C, Hansen HM, Month SR, Barcellos LF, et al. Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics. Cancer Causes Control. 2013;24(10):1789–95.CrossRefPubMedPubMedCentral
23.
Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2012;30(7):751–7.CrossRefPubMedPubMedCentral
24.
Orsi L, Rudant J, Bonaventure A, Goujon-Bellec S, Corda E, Evans TJ, et al. Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE). Leukemia. 2012;26(12):2561–4.CrossRefPubMed
25.
Lautner-Csorba O, Gezsi A, Semsei AF, Antal P, Erdelyi DJ, Schermann G, et al. Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance. BMC Med Genomics. 2012;5:42.CrossRefPubMedPubMedCentral
26.
Yang W, Trevino LR, Yang JJ, Scheet P, Pui CH, Evans WE, et al. ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia. 2010;24(4):894–6.CrossRefPubMedPubMedCentral
27.
Healy J, Richer C, Bourgey M, Kritikou EA, Sinnett D. Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia. Haematologica. 2010;95(9):1608–11.CrossRefPubMedPubMedCentral
28.
Gharbi H, Ben Hassine I, Soltani I, Safra I, Ouerhani S, Bel Haj Othmen H, et al. Association of genetic variation in IKZF1, ARID5B, CDKN2A, and CEBPE with the risk of acute lymphoblastic leukemia in Tunisian children and their contribution to racial differences in leukemia incidence. Pediatr Hematol Oncol. 2016;33(3):157–67.CrossRefPubMed
29.
Hsu LI, Chokkalingam AP, Briggs FB, Walsh K, Crouse V, Fu C, et al. Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children. Cancer Causes Control. 2015;26(4):609–19.CrossRefPubMedPubMedCentral
30.
Pastorczak A, Gorniak P, Sherborne A, Hosking F, Trelinska J, Lejman M, et al. Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population. Leuk Res. 2011;35(11):1534–6.CrossRefPubMed
31.
Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Koehler R, Greaves M, et al. Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood. 2010;115(9):1765–7.CrossRefPubMed
32.
Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193–203.CrossRefPubMed
33.
Jensen K, Schaffer L, Olstad OK, Bechensteen AG, Hellebostad M, Tjonnfjord GE, et al. Striking decrease in the total precursor B-cell compartment during early childhood as evidenced by flow cytometry and gene expression changes. Pediatr Hematol Oncol. 2010;27(1):31–45.CrossRefPubMed
34.
Zeng H, Wang XB, Cui NH, Nam S, Zeng T, Long X. Associations between AT-rich interactive domain 5B gene polymorphisms and risk of childhood acute lymphoblastic leukemia: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(15):6211–7.CrossRefPubMed
35.
Iqbal Z. Molecular genetic studies on 167 pediatric ALL patients from different areas of Pakistan confirm a low frequency of the favorable prognosis fusion oncogene TEL-AML1 (t 12; 21) in underdeveloped countries of the region. Asian Pac J Cancer Prev. 2014;15(8):3541–6.CrossRefPubMed
Metadata
Title
ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis
Authors
Ju-Le Yang
Yi-Ni Liu
Yong-Yi Bi
Hong Wang
Publication date
01-09-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02658-2

Other articles of this Issue 3/2019

International Journal of Hematology 3/2019 Go to the issue

Original Article

Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS

Guideline

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-6. Burkitt lymphoma (BL)

Original Article

Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens

Original Article

Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients

Original Article

Long-term outcome and chimerism in patients with Wiskott–Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey

Original Article

Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits